BetterLife Pharma (TSE:BETR) has released an update.
BetterLife Pharma Inc., a biotech firm specializing in non-hallucinogenic LSD derivatives for mood disorders, has published a patent for the treatment method of their product, BETR-001. The company emphasizes BETR-001’s potential to be self-administered for psychiatric and neurological disorders without the hallucinogenic side effects associated with first and second generation psychedelics. BetterLife is advancing towards human clinical trials, having completed necessary preclinical studies and planning to file an IND soon.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
